Minoru Fukuchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Minoru Fukuchi has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
Hideyuki Ishida
Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
40 shared publicationsKeiichiro Ishibashi
Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
40 shared publications- Erito Mochiki
Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe 350-8550, Saitama, Japan
29 shared publications Toru Ishiguro
Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
23 shared publicationsTakeaki Matsuzawa
19 shared publications- Youichi Kumagai
Department of Digestive Tract and General Surgery, Saitama Medical Center Saitama Medical University Saitama Japan
19 shared publications
Latest Publications
- 28 February 2020
- Published by International Institute of Anticancer Research in In Vivo
- Vol. 34  (2) , 903-908
Efficacy of Irinotecan as Third-line Chemotherapy for Unresectable or Recurrent Gastric Cancer
Aim: To evaluate the efficacy and safety of third-line chemotherapy (CTx) for patients with unresectable or recurrent gastric cancer (GC) refractory to S-1 with or without platinum and taxanes. Patients and Methods: We retrospectively analyzed clinicopathological and survival data of 26 patients who underwent third-line CTx. Results: Irinotecan therapy (odds ratio=0.12, 95% confidence interval=0.02-0.38; p<0.01) and ≥2 cycles of third-line CTx (odds ratio=0.01, 95% confidence intervaI=0.01-0.11; p<0.01) were independent predictors of longer progression-free survival in multivariate Cox regression analysis. In 18 patients (69%) receiving irinotecan, the overall response rate was 11%, and the disease control rate was 44%. Median progression-free and overall survival were 3.5 and 11.3 months, respectively. Ten patients (56%) had grade 3-4 toxicities, which were managed. Conclusion: Irinotecan therapy may become optimal and tolerated in the third-line setting to prolong progression-free survival by increasing the number of treatment cycles.
- 28 February 2020
- Published by International Institute of Anticancer Research in In Vivo
- Vol. 34  (2) , 903-908
Efficacy of Irinotecan as Third-line Chemotherapy for Unresectable or Recurrent Gastric Cancer
Aim: To evaluate the efficacy and safety of third-line chemotherapy (CTx) for patients with unresectable or recurrent gastric cancer (GC) refractory to S-1 with or without platinum and taxanes. Patients and Methods: We retrospectively analyzed clinicopathological and survival data of 26 patients who underwent third-line CTx. Results: Irinotecan therapy (odds ratio=0.12, 95% confidence interval=0.02-0.38; p<0.01) and ≥2 cycles of third-line CTx (odds ratio=0.01, 95% confidence intervaI=0.01-0.11; p<0.01) were independent predictors of longer progression-free survival in multivariate Cox regression analysis. In 18 patients (69%) receiving irinotecan, the overall response rate was 11%, and the disease control rate was 44%. Median progression-free and overall survival were 3.5 and 11.3 months, respectively. Ten patients (56%) had grade 3-4 toxicities, which were managed. Conclusion: Irinotecan therapy may become optimal and tolerated in the third-line setting to prolong progression-free survival by increasing the number of treatment cycles.
- 1 November 2018
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 38  (11) , 6473-6478
Prognostic Significance of Conversion Surgery Following Firstor Second-line Chemotherapy for Unresectable Gastric Cancer
Background/Aim: Advances in chemotherapy for gastric cancer have encouraged surgeons to perform conversion surgery following a response to first-line chemotherapy in patients with initially unresectable gastric cancer. In this study we evaluated the efficacy of conversion surgery following first- or second-line chemotherapy for unresectable gastric cancer. Patients and Methods: We retrospectively analyzed clinicopathological and survival data of 94 patients with unresectable gastric cancer treated with first- (n=94) or second-line (n=43) chemotherapy. Results: Patients who converted to surgery following first(n=26) or second-line (n=5) chemotherapy had significantly longer survival times than those treated with chemotherapy alone (n=63) (p<0.01). Survival length did not differ significantly between patients converted to surgery following first- and second-line chemotherapy. Among 31 patients who underwent conversion surgery, one initial non-curative factor (odds ratio(OR)=0.49; 95% confidence interval (95%CI)=0.22-0.95; p=0.03) was the only significant independent predictor of longer survival in multivariate Cox regression analysis. Conclusion: Patients with unresectable gastric cancer initially exhibiting one noncurative factor may obtain survival benefit from conversion surgery after a response to both first- and second-line chemotherapy.
- 1 November 2018
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 38  (11) , 6473-6478
Prognostic Significance of Conversion Surgery Following Firstor Second-line Chemotherapy for Unresectable Gastric Cancer
Background/Aim: Advances in chemotherapy for gastric cancer have encouraged surgeons to perform conversion surgery following a response to first-line chemotherapy in patients with initially unresectable gastric cancer. In this study we evaluated the efficacy of conversion surgery following first- or second-line chemotherapy for unresectable gastric cancer. Patients and Methods: We retrospectively analyzed clinicopathological and survival data of 94 patients with unresectable gastric cancer treated with first- (n=94) or second-line (n=43) chemotherapy. Results: Patients who converted to surgery following first(n=26) or second-line (n=5) chemotherapy had significantly longer survival times than those treated with chemotherapy alone (n=63) (p<0.01). Survival length did not differ significantly between patients converted to surgery following first- and second-line chemotherapy. Among 31 patients who underwent conversion surgery, one initial non-curative factor (odds ratio(OR)=0.49; 95% confidence interval (95%CI)=0.22-0.95; p=0.03) was the only significant independent predictor of longer survival in multivariate Cox regression analysis. Conclusion: Patients with unresectable gastric cancer initially exhibiting one noncurative factor may obtain survival benefit from conversion surgery after a response to both first- and second-line chemotherapy.
- 1 January 2018
- Published by International Institute of Anticancer Research in In Vivo
- Vol. 32  (1) , 145-149
Prognostic Impact of Splenectomy in Patients with Esophagogastric Junction Carcinoma
Background/Aim: We evaluated the survival benefit of splenectomy in patients with esophagogastric junction (ECJ) carcinoma. Patients and Methods: We retrospectively examined clinicopathological and survival data for 60 surgically-treated patients with ECJ carcinoma. Results: The 5-year overall survival (OS) rate was 47%. Splenectomy was performed in 20 patients (30%). Multivariate Cox regression analysis revealed splenectomy (odds ratio (OR), 2.70; 95% confidence interval (CI)=1.06-7.17; p=0.04) and venous invasion (OR=3.03; 95% CI=1.20-9.27; p=0.02) as significant independent predictors of poorer OS. Splenic hilar lymph node metastasis was not observed. Multivariate logistic regression analysis identified perioperative blood transfusion (BTF) as a significant independent factor associated with splenectomy. Conclusion: The survival benefit of splenectomy in ECJ carcinoma patients may decrease with increasing frequency of perioperative BTF for blood loss. We recommend that splenectomy should be performed carefully when indicated by the extent or invasion of EGJ carcinoma.
- 1 January 2018
- Published by International Institute of Anticancer Research in In Vivo
- Vol. 32  (1) , 145-149
Prognostic Impact of Splenectomy in Patients with Esophagogastric Junction Carcinoma
Background/Aim: We evaluated the survival benefit of splenectomy in patients with esophagogastric junction (ECJ) carcinoma. Patients and Methods: We retrospectively examined clinicopathological and survival data for 60 surgically-treated patients with ECJ carcinoma. Results: The 5-year overall survival (OS) rate was 47%. Splenectomy was performed in 20 patients (30%). Multivariate Cox regression analysis revealed splenectomy (odds ratio (OR), 2.70; 95% confidence interval (CI)=1.06-7.17; p=0.04) and venous invasion (OR=3.03; 95% CI=1.20-9.27; p=0.02) as significant independent predictors of poorer OS. Splenic hilar lymph node metastasis was not observed. Multivariate logistic regression analysis identified perioperative blood transfusion (BTF) as a significant independent factor associated with splenectomy. Conclusion: The survival benefit of splenectomy in ECJ carcinoma patients may decrease with increasing frequency of perioperative BTF for blood loss. We recommend that splenectomy should be performed carefully when indicated by the extent or invasion of EGJ carcinoma.
- 1 November 2017
- Vol. 44  (12) , 1461-1463
[Prognostic Impact of Tumor Location of Colorectal Cancer in Patients with Resected Liver Metastasis].
Recently, metastatic colorectal cancer(CRC)patients with a left-side primary tumor have been reported to have a significantly longer survival period than those with a right-side primary tumor. However, the impact of the location of the primary lesion on the survival outcomes of patients with resectable liver metastases of CRC has not yet been fully investigated. The subjects of this retrospective study were 113 consecutive patients who underwent a hepatic metastatectomy for CRC between 2001 and 2016 at our institution. The background data and survival times were compared between 32 patients whose primary lesions were located in the cecum or the ascending colon(right-side group)and 81 patients whose primary lesions were located in the descending colon, sigmoid colon, or rectum(left-side group). No significant differences in various clinicopathological variables were observed between the 2 groups. The 5-year overall and relapse-free survival rates after hepatectomy were 62.1% for the right-side group vs 49.2% for the left-side group(p=0.55)and 37.1% for the right-side group vs 33.4%for the left-sided group(p=0.76), respectively. In conclusion, colorectal liver metastasis should be resected regardless of the primary tumor location.
- 1 November 2017
- Vol. 44  (12) , 1461-1463
[Prognostic Impact of Tumor Location of Colorectal Cancer in Patients with Resected Liver Metastasis].
Recently, metastatic colorectal cancer(CRC)patients with a left-side primary tumor have been reported to have a significantly longer survival period than those with a right-side primary tumor. However, the impact of the location of the primary lesion on the survival outcomes of patients with resectable liver metastases of CRC has not yet been fully investigated. The subjects of this retrospective study were 113 consecutive patients who underwent a hepatic metastatectomy for CRC between 2001 and 2016 at our institution. The background data and survival times were compared between 32 patients whose primary lesions were located in the cecum or the ascending colon(right-side group)and 81 patients whose primary lesions were located in the descending colon, sigmoid colon, or rectum(left-side group). No significant differences in various clinicopathological variables were observed between the 2 groups. The 5-year overall and relapse-free survival rates after hepatectomy were 62.1% for the right-side group vs 49.2% for the left-side group(p=0.55)and 37.1% for the right-side group vs 33.4%for the left-sided group(p=0.76), respectively. In conclusion, colorectal liver metastasis should be resected regardless of the primary tumor location.
- 17 March 2017
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 37  (3) , 1343-1348
Efficacy of Conversion Surgery Following S-1 plus Cisplatin or Oxaliplatin Chemotherapy for Unresectable Gastric Cancer
Background/Aim: To evaluate the efficacy of conversion surgery following S-1 plus cisplatin (CS) or oxaliplatin (SOX) chemotherapy. Patients and Methods: We retrospectively analyzed clinicopathological and survival data of 74 patients with unresectable gastric cancer receiving CS or SOX. Results: Fifty-five and nineteen patients received CS and SOX, respectively. Conversion surgery (odds ratio (OR), 0.17; 95% confidence interval (CI), 0.04-0.64; p=0.01) was the only significant independent predictor of longer survival in multivariate Cox regression analysis. Patients (median age, 74 years) receiving SOX were significantly older than those receiving CS (median age=67 years) (p<0.01), although the rates of response, severe toxicity or conversion surgery did not differ significantly between the two treatment groups. Conclusion: Conversion surgery after a response to CS or SOX chemotherapy may have survival benefit in selected unresectable gastric cancer patients, for both non-elderly and elderly patients responding to SOX.
- 17 March 2017
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 37  (3) , 1343-1348
Efficacy of Conversion Surgery Following S-1 plus Cisplatin or Oxaliplatin Chemotherapy for Unresectable Gastric Cancer
Background/Aim: To evaluate the efficacy of conversion surgery following S-1 plus cisplatin (CS) or oxaliplatin (SOX) chemotherapy. Patients and Methods: We retrospectively analyzed clinicopathological and survival data of 74 patients with unresectable gastric cancer receiving CS or SOX. Results: Fifty-five and nineteen patients received CS and SOX, respectively. Conversion surgery (odds ratio (OR), 0.17; 95% confidence interval (CI), 0.04-0.64; p=0.01) was the only significant independent predictor of longer survival in multivariate Cox regression analysis. Patients (median age, 74 years) receiving SOX were significantly older than those receiving CS (median age=67 years) (p<0.01), although the rates of response, severe toxicity or conversion surgery did not differ significantly between the two treatment groups. Conclusion: Conversion surgery after a response to CS or SOX chemotherapy may have survival benefit in selected unresectable gastric cancer patients, for both non-elderly and elderly patients responding to SOX.
- 1 December 2016
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 36  (12) , 6699-6704
Efficacy of Nab-Paclitaxel as Second-line Chemotherapy for Unresectable or Recurrent Gastric Cancer
Aim: To evaluate the efficacy and safety of nanoparticle albumin-bound-paclitaxel (nab-PTX) as second-line chemotherapy (CT) for patients with unresectable or recurrent gastric cancer (GC). Patients and Methods: The clinicopathological and survival data of 37 patients with unresectable or recurrent GC who underwent nab-PTX monotherapy as second-line CT, were retrospectively analyzed. Results: The median number of cycles and relative dose intensity administered per patient were 5 and 90%, respectively. Their overall response rate was 24.3% and the disease control rate was 59.5%. Median progression-free survival (PFS) and overall survival were 4.8 months and 10.4 months, respectively. Thirteen patients had grade 3 or 4 toxicities and were managed. In multivariate Cox regression analysis, cycles of chemotherapy ≥5 (odds ratio, 0.20; 95% confidence interval, 0.08-0.50; p<0.01) was the only significant independent predictor of longer PFS. Conclusion: Nab-PTX may effectively prevent disease progression as second-line CT by increasing treatment cycles and managing adverse effects.
- 1 December 2016
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 36  (12) , 6699-6704
Efficacy of Nab-Paclitaxel as Second-line Chemotherapy for Unresectable or Recurrent Gastric Cancer
Aim: To evaluate the efficacy and safety of nanoparticle albumin-bound-paclitaxel (nab-PTX) as second-line chemotherapy (CT) for patients with unresectable or recurrent gastric cancer (GC). Patients and Methods: The clinicopathological and survival data of 37 patients with unresectable or recurrent GC who underwent nab-PTX monotherapy as second-line CT, were retrospectively analyzed. Results: The median number of cycles and relative dose intensity administered per patient were 5 and 90%, respectively. Their overall response rate was 24.3% and the disease control rate was 59.5%. Median progression-free survival (PFS) and overall survival were 4.8 months and 10.4 months, respectively. Thirteen patients had grade 3 or 4 toxicities and were managed. In multivariate Cox regression analysis, cycles of chemotherapy ≥5 (odds ratio, 0.20; 95% confidence interval, 0.08-0.50; p<0.01) was the only significant independent predictor of longer PFS. Conclusion: Nab-PTX may effectively prevent disease progression as second-line CT by increasing treatment cycles and managing adverse effects.
- 1 November 2016
- Vol. 43  (12) , 1711-1714
[Characteristics and Outcomes of Treatment in Patients with Stage IV Colorectal Cancer with Mismatch Repair Deficiency].
Mismatch repair(MMR)protein deficiency in colorectal cancer is well correlated with high-level microsatellite instability (MSI-H). There are little data on mismatch repair deficiency(dMMR)colorectal cancers in Japan. In addition, we have no available data on the therapeutic efficacy of oxaliplatin(oxa)-based chemotherapy, one of the standard treatment regimens for metastatic colorectal cancer, for patients with dMMR colorectal cancer. The subjects were 254 patients with Stage IV colorectal cancer whose tumors were immunohistochemically stained for MMR proteins, MLH1, MSH2, MSH6, and PMS2. Patients who underwent R0 resection were excluded. Clinicopathologic factors and the efficacy of oxa-based chemotherapy were compared between patients with dMMR colorectal cancer and those with mismatch repair proficient(pMMR)colorectal cancer. There were 7(2.8%)patients with dMMR. Four patients demonstrated both MLH1 and PMS2 loss, while 3 patients demonstrated both MSH2 and MSH6 loss. Though the dMMR had a higher frequency in female patients(p=0.02) and a lower frequency in those with liver metastasis(p<0.01), the other clinicopathologic factors evaluated did not significantly differ between the dMMR group and the pMMR group. One hundred and fifty patients with unresectable disease or R1/2 resection received first-line oxa-based chemotherapy. The median overall survival was 23.2 months and 16.2 months in patients with dMMR(n=4)and those with pMMR, respectively(n=146)(p=0.33). The frequency of dMMR amongStag e IV colorectal cancers was lower than those(4-11%)reported in Western countries. Therefore, the clinical significance of universal screeningfor dMMR in all colorectal cancer samples may not be valid. Concerningsurvival benefit, oxa-based chemotherapy seems to be an effective alternative in clinical practice for metastatic colorectal cancer patients with dMMR.
- 1 November 2016
- Vol. 43  (12) , 1711-1714
[Characteristics and Outcomes of Treatment in Patients with Stage IV Colorectal Cancer with Mismatch Repair Deficiency].
Mismatch repair(MMR)protein deficiency in colorectal cancer is well correlated with high-level microsatellite instability (MSI-H). There are little data on mismatch repair deficiency(dMMR)colorectal cancers in Japan. In addition, we have no available data on the therapeutic efficacy of oxaliplatin(oxa)-based chemotherapy, one of the standard treatment regimens for metastatic colorectal cancer, for patients with dMMR colorectal cancer. The subjects were 254 patients with Stage IV colorectal cancer whose tumors were immunohistochemically stained for MMR proteins, MLH1, MSH2, MSH6, and PMS2. Patients who underwent R0 resection were excluded. Clinicopathologic factors and the efficacy of oxa-based chemotherapy were compared between patients with dMMR colorectal cancer and those with mismatch repair proficient(pMMR)colorectal cancer. There were 7(2.8%)patients with dMMR. Four patients demonstrated both MLH1 and PMS2 loss, while 3 patients demonstrated both MSH2 and MSH6 loss. Though the dMMR had a higher frequency in female patients(p=0.02) and a lower frequency in those with liver metastasis(p<0.01), the other clinicopathologic factors evaluated did not significantly differ between the dMMR group and the pMMR group. One hundred and fifty patients with unresectable disease or R1/2 resection received first-line oxa-based chemotherapy. The median overall survival was 23.2 months and 16.2 months in patients with dMMR(n=4)and those with pMMR, respectively(n=146)(p=0.33). The frequency of dMMR amongStag e IV colorectal cancers was lower than those(4-11%)reported in Western countries. Therefore, the clinical significance of universal screeningfor dMMR in all colorectal cancer samples may not be valid. Concerningsurvival benefit, oxa-based chemotherapy seems to be an effective alternative in clinical practice for metastatic colorectal cancer patients with dMMR.
- 1 August 2016
- Vol. 36  (8) , 4237-41
Improved Efficacy by Addition of Protein-bound Polysaccharide K to Adjuvant Chemotherapy for Advanced Gastric Cancer.
To evaluate the efficacy of protein-bound polysaccharide K (PSK) added to S-1 adjuvant chemotherapy for treatment of advanced gastric cancer. We retrospectively examined clinicopathological and recurrence-free survival (RFS) data for 136 patients with stage II or III advanced gastric cancer who underwent S-1 adjuvant chemotherapy with or without PSK. Among 13 clinicopathological factors, non-T4 stage (odds ratio (OR)=0.61; 95% confidence interval (CI)=0.41-0.89; p<0.01), N0-1 (OR=0.65; 95% CI=0.43-0.95; p=0.03) and number of treatment cycles ≥7 (OR=0.37; 95% CI=0.20-0.67; p<0.01) were significant independent factors for better RFS. The number of treatment cycles of S-1 plus PSK was significantly higher than that of S-1 alone (p<0.01). S-1 adjuvant chemotherapy combined with PSK may reduce recurrence by prolonging the treatment cycles in patients with advanced non-T4 or N0-1 gastric cancer.
- 1 August 2016
- Vol. 36  (8) , 4237-41
Improved Efficacy by Addition of Protein-bound Polysaccharide K to Adjuvant Chemotherapy for Advanced Gastric Cancer.
To evaluate the efficacy of protein-bound polysaccharide K (PSK) added to S-1 adjuvant chemotherapy for treatment of advanced gastric cancer. We retrospectively examined clinicopathological and recurrence-free survival (RFS) data for 136 patients with stage II or III advanced gastric cancer who underwent S-1 adjuvant chemotherapy with or without PSK. Among 13 clinicopathological factors, non-T4 stage (odds ratio (OR)=0.61; 95% confidence interval (CI)=0.41-0.89; p<0.01), N0-1 (OR=0.65; 95% CI=0.43-0.95; p=0.03) and number of treatment cycles ≥7 (OR=0.37; 95% CI=0.20-0.67; p<0.01) were significant independent factors for better RFS. The number of treatment cycles of S-1 plus PSK was significantly higher than that of S-1 alone (p<0.01). S-1 adjuvant chemotherapy combined with PSK may reduce recurrence by prolonging the treatment cycles in patients with advanced non-T4 or N0-1 gastric cancer.
- 1 May 2016
- Vol. 36  (5) , 2481-5
Prognostic Factors for Gastric Cancer with Cancer Cells in the Peritoneal Cavity.
To identify the prognostic factors for gastric cancer with positive peritoneal cytology (CY1) or peritoneal metastasis (P1). We retrospectively analyzed clinicopathological and survival data of 78 patients who had undergone gastrectomy and/or S-1 based chemotherapy for CY1 or P1 gastric cancer. The median overall survival (OS) did not differ significantly between patients with CY1P0, CY0P1 and CY1P1 disease (24, 17 vs. 14 months, respectively). Among 12 clinicopathological factors, clinical N3 (odds ratio [OR]=2.18; 95% confidence interval [CI]=1.22-4.00; p=0.01) and gastrectomy not performed (OR=1.80; 95% CI=1.29-2.51; p<0.01) were significant independent prognostic factors. The median OS significantly differed between patients who had undergone gastrectomy plus chemotherapy versus chemotherapy alone (22 vs. 10 months, respectively; p<0.01). Gastrectomy and perioperative chemotherapy may both be indicated in CY1 or P1 gastric cancer patients with clinical N0-2.
- 1 May 2016
- Vol. 36  (5) , 2481-5
Prognostic Factors for Gastric Cancer with Cancer Cells in the Peritoneal Cavity.
To identify the prognostic factors for gastric cancer with positive peritoneal cytology (CY1) or peritoneal metastasis (P1). We retrospectively analyzed clinicopathological and survival data of 78 patients who had undergone gastrectomy and/or S-1 based chemotherapy for CY1 or P1 gastric cancer. The median overall survival (OS) did not differ significantly between patients with CY1P0, CY0P1 and CY1P1 disease (24, 17 vs. 14 months, respectively). Among 12 clinicopathological factors, clinical N3 (odds ratio [OR]=2.18; 95% confidence interval [CI]=1.22-4.00; p=0.01) and gastrectomy not performed (OR=1.80; 95% CI=1.29-2.51; p<0.01) were significant independent prognostic factors. The median OS significantly differed between patients who had undergone gastrectomy plus chemotherapy versus chemotherapy alone (22 vs. 10 months, respectively; p<0.01). Gastrectomy and perioperative chemotherapy may both be indicated in CY1 or P1 gastric cancer patients with clinical N0-2.
- Open Access
- 15 February 2016
- Published by Springer Nature in Surgical Case Reports
- Vol. 2  (1) , 15
Poorly cohesive adenocarcinoma of the ampulla of Vater: a case report
- 15 February 2016
- Published by Springer Nature in Surgical Case Reports
- Vol. 2  (1) , 15
Open AccessPoorly cohesive adenocarcinoma of the ampulla of Vater: a case report